Claim forms open for $533 million generic drug settlements
A federal court has authorized claim forms for a $533 million settlement involving generic drug manufacturers, including Sun Pharmaceutical and Sandoz. Eligible consumers and third-party payers who overpaid for generic drugs between May 1, 2009, and December 31, 2019, must file claims by November 9, 2026, to receive payments.
*this image is generated using AI for illustrative purposes only.
Eligible consumers and third-party payers who purchased certain generic drugs in the United States between May 1, 2009, and December 31, 2019, can now file claims to receive a share of $533 million in class action settlements. A federal court has granted final approval for the settlements, allowing Settlement Class Members to submit claim forms to recover overpayments allegedly caused by antitrust violations. The settlements involve Sun Pharmaceutical , Sandoz Inc., Apotex Corp., and Heritage Pharmaceuticals Inc., among others, in the lawsuit In re Generic Pharmaceuticals Antitrust Litigation.
The lawsuit alleges that generic manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers (EPPs) to pay inflated prices. The Settling Defendants deny any wrongdoing, and the litigation continues against Non-Settling Defendants. Four EPP Settlement Classes have been certified, one for each settlement, covering Consumers and Third-Party Payers such as insurers or employers with self-funded plans. The settlements exclude Indiana, Ohio, and certain entity types.
Settlement Breakdown
The total settlement fund of $533 million comprises contributions from multiple manufacturers to resolve consumer and Third-Party Payer claims. The following table details the amounts paid by each settling entity:
| Settling Defendant | Settlement Amount | Claims Covered |
|---|---|---|
| Sandoz | $275 million | Consumer and TPP claims |
| Sun/Taro | $200 million | Consumer and TPP claims |
| Apotex | $48 million | TPP claims |
| Heritage | $10 million | TPP claims |
After deducting notice and administration costs, attorney's fees, and litigation expenses, the remaining funds will be distributed proportionally to valid claimants. Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc. are collectively referred to as Sun/Taro in the settlement agreement.
How to File a Claim
To receive a payment, eligible class members must submit a claim form with supporting documentation. Claims can be filed online at the EPP Settlement Website or via a paper form postmarked by the deadline. The deadline for submission is November 9, 2026. Claimants do not need to sign up with a claims recovery firm or pay an additional law firm to participate.
Payment amounts depend on the total number of valid claims received and the claimant's documented spending on the Named Generic Drugs during the specified period. Failure to submit a claim form by the deadline will result in the forfeiture of any settlement benefits. Detailed information on the specific drugs included, class definitions, and claim procedures is available on the settlement website.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.17% | +3.45% | +8.80% | +11.89% | +15.94% | +189.79% |
How will the final settlement amounts be impacted by the number of valid claims submitted before the 2026 deadline?
What are the potential legal and financial consequences for the Non-Settling Defendants as the litigation continues?
Could this settlement set a precedent for future antitrust lawsuits against other generic drug manufacturers?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
